Kist, A. and Ho, A. D. and Räth, U. and Wiedenmann, B. and Bauer, A. and Schlick, E. and Kirchner, H. and Männel, Daniela N.
Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor.
Blood 72 (1), pp. 344-348.
Tumor necrosis factor (TNF), a protein predominantly produced by activated macrophages/monocytes, is presently available in recombinant, purified form for clinical trials. Intensive studies in many laboratories have shown that besides the tumorcytotoxic effects, TNF acts on a large array of different cells and has potent immunomodulatory activities. In a clinical phase I study, some immunologic ...
Export bibliographical data
|Institutions:||Medicine > Lehrstuhl für Immunologie|
|Cytotoxicity, Immunologic/drug effects||MESH|
|Immunosuppressive Agents/administration & dosage||MESH|
|Killer Cells, Natural/immunology||MESH|
|Lymphocyte Activation/drug effects||MESH|
|Recombinant Proteins/administration & dosage||MESH|
|Tumor Necrosis Factor-alpha/administration & dosage||MESH|
|Dewey Decimal Classification:||600 Technology > 610 Medical sciences Medicine|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Unknown|
|Deposited On:||20 Jun 2011 06:14|
|Last Modified:||13 Mar 2014 17:34|